Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae

Benzer Materyaller

• Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
  Yazar:: Peterson, James T., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
  Yazar:: Shiramoto, Masanari, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly
  Yazar:: Seo, Yu Bin, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Multiple colonization with S. pneumoniae before and after introduction of the seven-valent conjugated pneumococcal polysaccharide vaccine.
  Yazar:: Silvio D Brugger, ve diğerleri
  Baskı/Yayın Bilgisi: (2010-07-01)
• Multiple Colonization with S. pneumoniae before and after Introduction of the Seven-Valent Conjugated Pneumococcal Polysaccharide Vaccine
  Yazar:: Brugger, Silvio D., ve diğerleri
  Baskı/Yayın Bilgisi: (2010)